BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass. and BEIJING, China, Feb. 07, 2018 -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the LEERINK Partners 7^th Annual Global Healthcare Conference in New York, NY. The presentation is scheduled for 9:00 AM ET on Wednesday, February 14, 2018.

A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 850 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE^® (nanoparticle albumin–bound paclitaxel), REVLIMID^® (lenalidomide), and VIDAZA^® (azacitidine) in China under a license from Celgene Corporation.ⁱ

Investor Contact       
Lucy Li, Ph.D.         
+1 781-801-1800    
[email protected]                                           

Media Contact
Liza Heapes
+ 1 857-302-5663
[email protected] 

ⁱ ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.